

DSM Pharmaceutical Products

45 Waterview Blvd
Parsippany, NJ 07054-1298

DSM Pharmaceuticals Inc. Announces New Fill-Finish Service Capabilities for Injectable Cytotoxic Products

(Parsippany – September 28, 2007)

DSM Pharmaceuticals Inc., a leading global provider of aseptic manufacturing and development services to the pharmaceutical and biopharmaceutical industries, announces today the addition of aseptic fill-finish manufacturing services for injectable cytotoxic products. The facility will be ready for commercial production in January.

Aseptic Cytotoxic capabilities include flexible commercial scale fill-finish services for liquid and lyophilized products in vial sizes up to 65ml. The dedicated suites use RABS systems to ensure product isolation and include a TL filler and a BOC Edwards freeze dryer.

“As a recognized leader in aseptic manufacturing services, with innovations such as Lyo-Advantage and Liquid Advantage, DSM now brings their experience and knowledge to the next level with the addition of Cytotoxic fill-finish services,” says Terry Novak, President DSM Pharmaceuticals Inc. “The market for injectable cytotoxic products is expected to grow at double-digit levels over the next 5 years as evidenced by the number of customers interested in our Cytotoxic capabilities.”

About DSM Pharmaceuticals Inc.

DSM Pharmaceuticals, Inc. a business unit of DSM Pharmaceutical Products, is a global provider of custom manufacturing services to the pharmaceutical and biopharmaceutical industries. Our breadth of manufacturing services include the areas of steriles, orals and topicals, including dose form manufacturing, scheduled drugs, clinical manufacturing, fill finish manufacturing, and lyophilization services.

About DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products.

From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers' unique manufacturing needs.

About DSM

DSM is active worldwide in [nutritional and pharma ingredients, performance materials and industrial chemicals](#). The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and

animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named [Vision 2010 – Building on Strengths](#), focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with [locations](#) in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com.

Forward-looking statements

This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.

For more information:

DSM Pharmaceutical Products

Terry Novak

President

DSM Pharmaceuticals Inc.

+1-973-257-8471

Terry.Novak@dsm.com